These findings establish TMOD2 and DOCK4 as clinically actionable biomarkers that bridge the gap between molecular pathogenesis and therapeutic intervention, with single-cell validation confirming their cellular relevance, offering immediate opportunities for enhanced early detection, risk stratification, and precision medicine approaches in colorectal adenoma management, ultimately advancing our capacity to prevent CRC through targeted intervention at the precancerous stage. The gene discussed is TMOD2; the disease is colorectal adenoma.